IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. decreased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,039,819 shares of the medical research company's stock after selling 10,093 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.59% of IQVIA worth $183,320,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Continuum Advisory LLC lifted its stake in IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after acquiring an additional 64 shares in the last quarter. ST Germain D J Co. Inc. lifted its position in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares in the last quarter. New York Life Investment Management LLC grew its holdings in shares of IQVIA by 0.4% in the fourth quarter. New York Life Investment Management LLC now owns 23,086 shares of the medical research company's stock valued at $4,537,000 after purchasing an additional 81 shares in the last quarter. Zions Bancorporation N.A. lifted its holdings in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its position in IQVIA by 10.7% in the 4th quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock valued at $182,000 after buying an additional 90 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQVIA stock traded up $2.14 on Wednesday, reaching $164.75. 1,260,815 shares of the stock were exchanged, compared to its average volume of 1,649,294. The firm has a market capitalization of $28.50 billion, a PE ratio of 22.44, a PEG ratio of 1.75 and a beta of 1.30. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The business has a fifty day moving average price of $149.96 and a two-hundred day moving average price of $173.80. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The firm's quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.54 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on IQV. Wall Street Zen cut shares of IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. HSBC downgraded shares of IQVIA from a "buy" rating to a "hold" rating and lowered their target price for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. Robert W. Baird cut their price target on IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Finally, JPMorgan Chase & Co. lowered their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $226.32.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.